Deciding when triple therapy will be beneficial for COPD

1. Hancox RJ, Jones S, Baggott C, et al. New Zealand COPD Guidelines: Quick Reference Guide. N Z Med J 2021;134(1530):76–110. https://www.asthmafoundation.org.nz/health-professionals/management-guidelines/nz-copd-guidelines

2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2024. https://goldcopd.org/2024-gold-report/

3. Hoogendoorn M, Hoogenveen RT, Rutten-van Mölken MP, et al. Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur Respir J 2011;37(3):508–15.

4. Ho TW, Tsai YJ, Ruan SY, et al. In-hospital and one-year mortality and their predictors in patients hospitalized for first-ever chronic obstructive pulmonary disease exacerbations: a nationwide population-based study. PLoS One 2014;9(12):e114866.

5. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60(11):925–31.

6. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177(1):19–26.

7. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775–89.

8. Cates C. Inhaled corticosteroids in COPD: quantifying risks and benefits. Thorax 2013;68(6):499–500.

9. Mathioudakis AG, Bate S, Sivapalan P, et al Rethinking blood eosinophils for assessing ICS response in COPD: A post hoc analysis from FLAME. Chest 2024; 9 July online.